Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer and Eye Metastasis: Disease Relapse or a New Entity? by ZAROGOULIDIS, Paul et al.
 
 
Med Hypothesis Discov Innov Ophthalmol. 2016; 5(4)  
 
 
 
Short Communication 
      Medical Hypothesis, Discovery &Innovation 
Ophthalmology Journal 
 
 
 
Tyrosine Kinase Inhibitors for Non-Small Cell Lung Cancer 
and Eye Metastasis: Disease Relapse or a New Entity? 
Paul ZAROGOULIDIS 1 ; Sofia LAMPAKI 1 ;  Panos CHINELIS 1 ; George LAZARIDIS 2 ; Sofia BAKA 3 ; Aggeliki RAPTI 4 
 
1. Pulmonary Department, Oncology Unit, G. Papanikolaou General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece 
2. Oncology Department, G. Papageorgiou University General Hospital, Thessaloniki, Greece 
3. Oncology Department, Interbalkan European Medical Center, Thessaloniki, Greece 
4.Pulmonary Department, Sotiria Hospital of Chest Diseases, Athens, Greece 
 
ABSTRACT 
Lung cancer is still diagnosed during the advanced stage of the disease and most patients do not have the opportunity 
for surgical treatment, despite the new diagnostic equipment that has been made available in recent years, such as the 
radial and linear endobronchial ultrasound (EBUS) and electromagnetic fiberoptic bronchoscopy. However, novel 
targeted therapies with second generation tyrosine kinase inhibitors and immunotherapy are available. In this 
commentary, we will focus on eye metastasis after initiation of tyrosine kinase inhibitors due to epidermal growth factor 
mutation of lung cancer adenocarcinoma. 
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INTRODUCTION 
Lung cancer still remains the leading cause of cancer in 
male cancer patients and very soon it will be the leading 
cause of cancer death among women (1). Disease 
symptoms are such that patients are not diagnosed until 
they are in an advanced stage. Since most patients are 
smokers, a non-specific cough is usually attributed to 
their smoking habit. Only patients with hemoptysis are 
typically worried and seek medical attention. We still do 
not have a blood test that could be used as an early 
diagnostic marker, such as those used in prostate or 
gastrointestinal cancers (2). Non-small cell lung cancer 
treatment had a breakthrough in the past 15 years with 
tyrosine kinase inhibitors, specifically with the first 
generation erlotinib and gefitinib and, currently, with the 
second generation afatinib. These agents are referred to 
as ``targeted`` therapy since they target epidermal 
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growth factor mutations in lung cancer adenocarcinoma 
patients (3-8). The most common side effects of these 
agents are skin rash and gastrointestinal disorders, 
making them safer as therapy. It has been observed that 
more severe side effects are associated with a higher 
treatment efficiency. In the past two years, clinical 
physicians have also searched for epidermal growth 
factor mutations in mixed non-small cell lung cancer 
patients (adenocarcinoma and squamous, or squamous 
alone) in an effort to determine whether tyrosine kinase 
inhibitors would be effective in these patients (9, 10). 
Current guidelines indicate that for epidermal growth 
factor mutations, these agents should be used as first-
line treatment. However, disease relapse has been 
observed by many clinical physicians during the course of 
treatment. ``Relapse`` still has not been correctly 
identified in patients receiving chemotherapy. For 
example, we are still evaluating these patients with the 
response evaluation criteria in solid tumors (RECIST), 
even though we are not sure if these criteria should be 
applied to these patients (11-13). A very serious issue 
that has not been answered is whether all tumor sites 
have epidermal growth factor receptor (EGFR) mutations. 
In tissue samples from the primary site, we typically find 
that the newly diagnosed adenocarcinoma is EGFR 
positive; however, we do not know if the metastatic sites 
are also EGFR positive. We assumed that they are and we 
studied the response using the RECIST criteria. There are 
some treatment proposals for the treatment options 
after disease relapse when a patient receives tyrosine 
kinase inhibitors (TKIs). In regards to targeted therapy 
options, there is the option of a re-biopsy of the primary 
lesion or at a new metastatic site. If the T790 mutation is 
observed, then osimertinib is a treatment option (14). It 
has also been reported that crizotinib, another TKI that is 
used to treat an anaplastic lymphoma kinase (ALK) 
mutation, is able to efficiently block uveal metastasis (15-
17). In regards to gefitinib, there is data that indicate that 
it can be used efficiently for blocking choroidal 
metastasis as well as for treating choroidal metastasis 
(18). Moreover, it has been previously reported that 
several molecular pathways are deregulated, usually by 
overexpression, which induces TKI resistance. The same 
pathways have been identified in uveal metastasis of a 
lung adenocarcinoma under conditions of treatment with 
TKI (19, 20). It has been observed that afatinib, which is a 
second generation TKI, has been used to effectively treat 
and control brain metastasis (21). In our institute we 
recently diagnosed a patient with adenocarcinoma (a 50-
year-old woman, non-smoker, and EGFR positive) and we 
administered afatinib. Upon diagnosis, the patient was 
identified to be at stage IV due to 3 metastatic sites in 
the brain with local edema (an oral suspension of 
dexamethasone was also initiated). She received afatinib 
(40 mg) and brain irradiation. Due to severe adverse 
effects, which were mostly gastrointestinal, the dosage 
was lowered to 20 mg within 60 days of initiation (Figure 
1). 
 
Figure 1. CT scan of the brain after irradiation 
 
However, eye puffiness slowly developed around the 
right eye and an MRI revealed local tissue. The repeat 
biopsy also revealed an adenocarcinoma without EGFR 
mutation. Although we could have changed the 
treatment to chemotherapy, we considered this progress 
an oligometastatic disease progression and decided to 
continue with afatinib until disease progression in the 
primary site. We decided to evaluate the primary site 
within the following two months (two months after 
diagnosis and treatment initiation with the TKI). Based on 
the current data re-biopsy of the eye metastasis should 
be performed if there is an easy approach. The tissue 
could provide us information regarding the biological 
behavior of the metastatic site and future solutions for 
treatment. For example in our case if T790 is observed 
then osimertinib could be considered. The major issue 
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that still remains is whether we should biopsy sites other 
than the primary cancer site or biopsy metastatic sites as 
a gold standard for the approach to treatment (16, 22-
30). 
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